Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN versus PHENYTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN versus PHENYTEX.
GABAPENTIN vs PHENYTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin is a structural analog of GABA but does not bind to GABA receptors. It binds to the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and decreasing the release of excitatory neurotransmitters.
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Also enhances GABA-mediated inhibition.
Initial dose: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate as needed up to 1800-3600 mg/day in three divided doses. Maximum single dose: 1200 mg. Dose adjustments for renal impairment should be made based on creatinine clearance.
300-400 mg/day orally in divided doses, typically 100 mg three times daily or 200 mg twice daily; loading dose 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) at 2-hour intervals, or 10-15 mg/kg IV at a rate not exceeding 50 mg/min.
None Documented
None Documented
Clinical Note
moderateGabapentin + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone propionate."
Clinical Note
moderateGabapentin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Gabapentin."
Clinical Note
moderateGabapentin + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Gabapentin."
Clinical Note
moderateGabapentin + Clemastine
5-7 hours (normal renal function); prolonged to 50-140 hours in end-stage renal disease; half-life independent of dose due to linear kinetics.
22 hours (range 7-42 hours; prolonged in hepatic impairment; clinical context: steady-state achieved in 5-7 days)
Renal: 76-81% unchanged in urine; biliary/fecal: <5% as metabolites; remainder (10-20%) as minor metabolites via urine.
Renal (hepatic metabolism to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal excretion minimal)
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Clemastine."